

Global Markets Daily Mixed Sentiments

Dovish FoMC Minutes; Biden Proposed Higher Tax Rate

Markets were mixed and largely subdued overnight. FoMC minutes released overnight underscored Fed's dovish stance. Minutes reiterated FOMC's focus on making 'actual progress' towards their inflation and employment mandates and not 'forecast progress' when determining future trajectory path of Fed fund rate and balance sheet. Biden Administration unveiled its plan overnight to overhaul the corporate tax code, including the proposal of raising of corporate tax rate to 28%, from 21%, increasing the GILTI global minimum tax rate to 21% and also include efforts to combat climate change, proposing to replace fossil subsidy with tax incentives that promote clean energy production. If enacted, the plan would raise \$2.5tn in revenue over 15 years. A dovish FoMC and lesser reliance on borrowing (but higher taxes, if passed) should see a slower pace of UST yield increases (if not lower), and to some extent, weigh on USD.

RBI QE

1m USDINR NDF extended its run-up to intra-day high of 74.87 this morning. This is largely in reaction to the official QE by RBI at the end of its monetary policy decision yesterday. The Reserve Bank had finally made an official bond purchase program, pledging to buy an initial package of INR1trn (\$14bn) worth of government bonds in a bid to crimp on the rising domestic yields, in addition to a pledge to keep its policy stance accommodative. This comes as the nation faces a rapidly rising rate of infection that has exceeded the peak in last Sep. India recorded 115.7k new cases for 6 Apr. The Reserve bank had hoped to clamp down on the borrowing costs to support growth. Maharashtra had announced fresh restrictions since the start of the week in reaction to the rise in infection - the state contributes to 60% of daily nation infection rates. The debt buying program will focus on government securities in the secondary market and the package is for 1Q FY2022.

Focus on German Factory Orders Today

Data of interest today include US initial jobless claims; EU PPI (Feb); German factory orders (Feb); UK construction PMI.

FX: Overnight Closing Prices									
		: Overnight	Closing Prices	-					
Majors	Prev	% Chg	Asian FX	Prev	% Chg				
Majors	Close	∕₀ clig		Close	∕₀ cing				
EUR/USD	1.1868	-0.07	USD/SGD	1.3413	n 0.17				
GBP/USD	1.3737	🚽 -0.63	EUR/SGD	1.5918	n 0.10				
AUD/USD	0.7614	🞍 -0.65	JPY/SGD	1.2208	n 0.05				
NZD/USD	0.7013	🞍 -0.65	GBP/SGD	1.8425	🞍 -0.47				
USD/JPY	109.85	n 0.09	AUD/SGD	1.0211	🚽 -0.50				
EUR/JPY	130.39	n 0.05	NZD/SGD	0.9406	🚽 -0.49				
USD/CHF	0.9303	-0.06	CHF/SGD	1.4426	n 0.29				
USD/CAD	1.2609	^ 0.34	CAD/SGD	1.0638	-0.16				
USD/MYR	4.1315	J-0.04	SGD/MYR	3.0844	^ 0.12				
USD/THB	31.381	n 0.27	SGD/IDR	10819.63	n 0.00				
USD/IDR	14495	-0.07	SGD/PHP	36.3111	n 0.18				
USD/PHP	48.6	n 0.06	SGD/CNY	4.8853	n 0.07				
Im	plied USD/S	GD Estimate	es at 8 April 20	21, 9.00am					
Upper Band L	Upper Band Limit Mid-Point			Lower Band Limit					
1.3279		1.3550	1.3821						

Analysts

Saktiandi Supaat (65) 6320 1379 saktiandi@maybank.com.sg

Christopher Wong (65) 6320 1347 wongkl@maybank.com.sg

Fiona Lim (65) 6320 1374 fionalim@maybank.com.sg

Tan Yanxi (65) 6320 1378 tanyx@maybank.com.sg

G7: Events & Market Closure

Date	Ctry	Event
5 Apr	AU, NZ, UK	Market closure
6 Apr	AU	RBA Policy Decision

Asia Ex JP: Events & Market Closure

Date	Ctry	Event
5 Apr	HK, TW	Market Closure
6 Apr	HK, TH	Market Closure
7 Apr	IN	RBI Policy Decision

G7 Currencies

DXY Index - Mixed, Subdued. Markets were mixed and largely subdued overnight. FoMC minutes released overnight underscored Fed's dovish stance. Minutes reiterated FOMC's focus on making 'actual progress' towards their inflation and employment mandates and not 'forecast progress' when determining future trajectory path of Fed fund rate and balance sheet. It also noted that it would likely be "some time until substantial further progress toward the committee's maximum employment and price stability goals would be realised". Separately in an interview with CNBC, Fed's Brainard said it was likely that bottlenecks could result in a temporary lift in inflation but after that, it is "more likely that the entrenched inflation dynamics we have seen for well over a decade will take over". She emphasized that monetary forward guidance is premised on outcomes not the outlook. On tax, the Biden Administration unveiled its plan to overhaul the corporate tax code, including the proposal of raising of corporate tax rate to 28%, from 21%, increasing the GILTI global minimum tax rate to 21% and also include efforts to combat climate change, proposing to replace fossil subsidy with tax incentives that promote clean energy production. If enacted, the plan would raise \$2.5tn in revenue over 15 years. Treasury Secretary Yellen said that US tax revenues are already at lowest level in generations and if they continue to drop lower, the US will have less money to invest in roads, bridges, broadband, etc. For reference, tax levied on corporate profits as % share of GDP is sub-1% for US and as high as above 4% for Japan while the OECD average is slightly above 3% of GDP. A dovish FoMC and lesser reliance on borrowing but higher taxes should see a slower pace of UST yield increases, and to some extent, weigh on USD. Elsewhere on AstraZeneca vaccine, EU and UK officials said there is a "possible link" with rare blood clots but benefits outweigh risks. The European Medicines Agency had received 164 cases of brain blood clots after 34mn doses of vaccines were administered. This could undermine sentiment if more countries start to halt the use of AstraZeneca vaccines. USD was a touch firmer overnight but price action was largely subdued. Last seen at 92.45 levels. Mild bearish momentum on daily chart intact while the decline in RSI moderated. Support here at 92.30/35 (61.8% fibo, 21DMA). Sustained close below this needed for further downside towards 91.75 (50% fibo retracement of Nov high to Jan low) to pan out. Resistance at 92.5 (200 DMA), 93.10 (76.4% fibo), 93.4 (2021 high). Week remaining brings initial jobless claims today and PPI (Mar); Wholesale inventories, Trade Sales (Feb) tomorrow.

EURUSD - German Factory Orders Eyed. EUR's rise above 1.19handle was reversed into losses overnight. Price action suggests price rejection of its recent run-up. To some extent yesterday's session resembled a shooting star pattern - typically associated with bearish reversal risks. Pair was last at 1.1865 levels. Mild bullish momentum on daily chart intact while rise in RSI slows. Bullish pressure showing tentative signs of slowing. Immediate resistance still at 1.1895 (200 DMA), 1.1950 levels. Support at 1.1850 (21 DMA), 1.18 levels. Week remaining brings PPI (Feb); German factory orders (Feb) on Thu; German IP, trade, current account (Feb) on Fri. We respect price action and acknowledge the risk of a near-term pullback. But we maintain a constructive outlook on EUR, on expectations of vaccine ramp-up and the eventual repricing for EU reopening. Though all EU member nations will reach herd immunity at the same time, major EU nations such as Germany, France, Italy, Spain and Netherlands are likely to have inoculate more than 55% of their total population by end-Jun. European Commission expects delivery of vaccines to increase to about 360mio doses in 2Q, from just over 100mio doses in 1Q. EU Commissioner Breton said the EUbloc will have the capacity to deliver enough doses to reach collective immunity by 14 Jul, provided the doses are injected

GBPUSD - Buy Dips. GBP extended its decline overnight. Astrazeneca vaccine's possible link with rare blood clots may undermine sentiment here as UK is one of the major users of the Astra vaccine. We earlier noted that first dose program will be paused as remaining supplies (disrupted due to a hold-up in 5mio doses from India that 1.7mio doses require re-testing) are focused on ensuring people receive their second doses within the promised 12-week limit. All in, prior rapid pace of inoculation is likely to slow, chipping away GBP's vaccine-lead premium. GBP was last seen at 1.3750 levels. Daily momentum and RSI are not indicating a clear bias. Look for consolidative price action ahead. Immediate support at 1.3720, 1.3680 (100 DMA). Resistance at 1.3810 (23.6% fibo), 1.3890 levels. Week remaining brings Construction PMI (Mar) on Thu. Beyond the near term, we maintain a constructive outlook on vaccine lead and gradual exit out of pandemic (as country detail reopening plans). Pent-up demand (BoE Chief Economist Haldane said that excess savings is now about GBP150bn and we note that this is a 50% improvement from a quarter ago) could overwhelm when restrictions are eventually eased and economy reopens.

USDJPY - Upsides Capped. Last seen at 109.82, roughly on par with where it was yesterday morning. USD and UST yield down-moves stalled yesterday, even as Fed officials continued to assure markets that inflation risks are likely transitory. UST 10Y yields could still be resisted by interim peak near 1.75% for now and upsides in USDJPY could be capped alongside. Momentum on daily chart is mildly bearish while RSI has exited overbought territory. Support at 109.40 (21-DMA), 108.20 (61.8% fibo retracement of Mar 2020 high to Dec low). Resistance at 111.00, 111.70 (Mar 2020 high). Leading index CI for Feb (P) came in at 99.7, improving from 98.5 prior. Current account for Feb came in at a surplus of JPY2,917bn, stepping up from JPY644.4bn prior, likely positive for JPY sentiments.

NZDUSD - Consolidate. NZD turned lower yesterday after failing to make a decisive break above its 21DMA resistance. Pair was last seen at 0.7010 levels. Mild bullish momentum intact while RSI is easing. Resistance at 0.7075 (21 DMA) need to be broken for further upside to extend toward 0.7140 (100 DMA). Support at 0.7000, 0.6950 levels. Week remaining brings Business confidence, Activity Outlook (Apr) on Fri. AUDUSD - Bearish Reversal, Back in Range. AUDUSD made a bearish reversal at mid-week, weighed by the USD gains. The safe haven greenback is back in demand amid new UK and EU findings that the AstraZeneca vaccine is possibly linked to very rare cases of blood clots. The European Medicines Agency had received 164 cases of brain blood clots after 34mn doses of vaccines were administered. At home, PM Morrison said that the rollout of the vaccine remains regardless given that there is no advisory to change. Back on the AUDUSD chart, this pair continue to remain within the 0.7560-0.7660 range, last printed 0.7610. A breakout of the range is required for fresh directional cues. Next resistance at 0.7770 and then at 0.7870. Support at 0.7560, 0.7500 (50% fibo retracement of the Oct-Feb rally) before the next at 0.7380 (61.8% fibo). Data-wise, FX Reserves (Mar) and Financial Stability Review would be watched on Fri.

USDCAD - Sell on rally. USDCAD hovered around 1.2620 as risk appetite weakens on vaccine concerns. The combination of softening oil and firmer USD lifted this pair to test the 50-dma at 1.2626. Some focus remains on the US-Iran relations as the State Department stated on Wed that US can remove sanctions on Iran to comply with the 2015 nuclear deal. Iran wants sanctions to be lifted before a face-to-face meeting. Another drag on the CAD comes from within. Ontario declared a state of emergency. >14.7mn people are ordered to stay home from 8 Apr 12.01am. Most stores will shut with customers served only via delivery or outdoor pick-up for the next 4 weeks. Back on the USDCAD chart, MACD and stochastics have turned a tad more bullish. Resistance first at 1.2626 (50-dma) before the next at 1.2715 (100-dma). We continue to prefer to sell the USDCAD on rally as we see a potential for CAD to be on a late but aggressive rally. Key underpinnings include a recovering global environment should be broadly supportive of crude oil, Canada's strong, decisive and constant fiscal support, along with the acceleration of its mass inoculation at home that should translate to stronger economic outcomes in a matter of time. We do think that vaccination progress will speed up from the current inoculation of 1.66% of population fully vaccine). 12mn doses of Moderna is expected between Apr and end June while Pfizer-BioNTech will ship more than 1mn doses a week in Apr and May, more than 2mn every week in June for a total of 17.8mn within Spring. Beyond the nearby support at 1.2500, the next support is seen at 1.24/1.2365. Data-wise, this week has Mar labour report on Fri

Asia ex Japan Currencies

SGD trades around +1.03% from the implied mid-point of 1.3550 with the top estimated at 1.3279 and the floor at 1.3821.

- **USDSGD** *Ranged*. Pair last seen at 1.3413, rising modestly after hitting interim low near 1.3380 yesterday. Broad USD down-move largely stalled as earlier triggers (i.e., IMF's reaffirmation of global synchronous recovery narrative negative for countercyclical USD; UST yields softening earlier in the week) faded. With SGD NEER still testing the 1.0% resistance level (i.e., SGD outperformed peers recently), down-moves in USDSGD could be more challenging. Interim ranged trading around the 1.34-handle possible. Momentum on daily chart is modestly bearish while RSI is not showing a clear bias. Resistance at 1.3480, 1.3510 (200-DMA). Support at 1.3340 (100-DMA), 1.3300. Labor market data reflects a continuing recovery in the jobs market. Unemployment rate fell to 3.0% in Feb, from 3.2% in Jan. Resident unemployment rate also declined to 4.1%, from 4.3% prior.
- AUDSGD Consolidative. AUDSGD waffled around 1.0210 this morning weighed by AUD downmove. Price action remains stuck within 1.0200-1.0320. Bearish MACD forest intact. 21-dma converges towards the 50-dma at around 1.0308, forming a resistance area. Beyond the 1.0200, support at 1.0090.
- SGDMYR Range. SGDMYR remains well-supported; last seen at 3.0890 levels. Mild bullish momentum on daily chart intact while RSI is rising towards near-overbought conditions. Mild risks to the upside. Resistance at 3.09, 3.0970 levels. Support at 3.0730 (21 DMA), 3.0680 (38.2% fibo retracement of 2020 low to high). We look for 3.0800 - 3.0900 range intra-day.
- USDMYR *Rebound*. USDMYR rebounded after failing to break below its 200DMA support decisively. Pair was last at 4.1430 levels. Bearish momentum on daily chart intact while RSI showed tentative signs of rising. Look out for consolidative price action. Support at 4.1030 (23.6% fibo). Resistance at 4.13 (21 DMA) 4.1580 levels.
- **USDCNH** *Rising Wedge Intact For Now*. USDCNH rose a tad, guided by the broadly firmer greenback, last seen around 6.5550. Resistance remains at 6.5890, 6.60. The rising wedge formation could be broken out soon and diagonal support is marked by the 21-dma at 6.53 before 6.50. Week ahead has foreign reserves for Mar on Wed and inflation prints on Fri along with possibly credit data for Mar that is due between 9-15th. In news from home, China will invest more in less developed and poor regions in the next five years.
- 1M USDINR NDF Catapulted. The NDF rallied from lows of 73.66 to levels around 74.80 as we write, making it the biggest mover in an otherwise sluggish Asian session. The price had reacted to the official QE by RBI at the end of its monetary policy decision yesterday. The Reserve Bank had finally made an official bond purchase program, pledging to buy an initial package of INR1trn (\$14bn) worth of government bonds in a bid to crimp on the rising domestic yields, in

addition to a pledge to keep its policy stance accommodative. This comes as the nation faces a rapidly rising rate of infection that has exceeded the peak in last Sep. India recorded 115.7k new cases for 6 Apr. The Reserve bank had hoped to clamp down on the borrowing costs to support growth. Maharashtra had announced fresh restrictions since the start of the week in reaction to the rise in infection - the state contributes to 60% of daily nation infection rates. The debt buying program will focus on government securities in the secondary market and the package is for 1Q FY2022. Separately, the central bank also declared variable rate reverse repo auctions (that tenors) that will offer banks slightly higher interest rates on their surplus cash holding deposits (with RBI). Growth forecast is kept unchanged at 10.5% for FY2022 and inflation is revised higher to 5.2% for 1H and RBI note upside risks to core inflation on higher input costs. For the 1M NDF, momentum continues to be bullish for this pair and 75.36 marks the next key resistance. Interim resistance at 74.95. Support at 73.95 (200-dma). .

1M USDIDR NDF - Step-Up on Central Bank Independence Concerns; Fade Rallies. NDF last seen at 14650, almost 1% higher vs. levels seen vesterday morning. President Jokowi is backing the expansion of BI's mandate to include sustainable economic growth and job creation, with the move seen by some as threatening central bank independence. Earlier, IMF also cut Indonesia's growth projection this year to 4.3% from January's 4.8%, which could have weighed on IDR sentiments as well. Nonetheless, earlier risks from rising US treasury yields seems to have eased for now. With recent IDR negativity being priced in to a significant extent, we prefer to fade up-moves in the NDF. Momentum and RSI mildly bearish. on daily chart are Immediate resistance at 14,660 (recent high), before 14,850 (76.4% fibo retracement from Sep 2020 high to Feb 2021 low). Support at 14,520 (21-DMA), before 14,240 (100-DMA).

USDTHB - Supported. Last seen at 31.44, seeing a step-up this morning. THB sentiments were likely negatively impacted by BoT minutes released yesterday, which revealed that a worse-case scenario in which foreign arrivals shrank to 100k this year could see the economy contract by -1.7% alongside (vs. 3% growth and 3mn tourist arrivals in the base-case). Downside risks include delayed border reopening, lower support from fiscal stimulus and rising bad debt. Authorities may be preparing for a possible spike in Covid cases after the UK Covid-19 variant was detected. Worsening in contagion could lead THB sentiments to remain soft and USDTHB to remain supported in the interim. Nonetheless, TA still suggests that recent USDTHB up-moves look stretched. Bullish momentum on daily chart is fading while RSI is in overbought territory. Support at 31.00 (21-DMA), 30.80 (200-DMA), 30.30 (100-DMA). Resistance at 31.30 (76.4% fibo retracement from Sep 2020 high to Dec 2020 low) has been breached, next at 31.70 (Sep 2020 high).

IM USDPHP NDF - Supported. NDF last seen at 48.92, still on the climb yesterday. Domestically, the Covid case surge is still worrying, with 7-day average in new cases hitting >10k (on 6 Apr) from around 2k in late Feb. We also note some concerns on the FDI front. President Duterte recently vetoed a provision under the CREATE bill which would have allowed existing registered businesses to apply for

extended incentives for the same activity, viewing that fresh incentives should be allocated to new activities instead. The Philippine Economic Zone Authority noted that this could lead to outflows from existing FDI investors in the country. Momentum and RSI on daily chart are mildly bullish. NDF could be supported in the interim. Resistance at 49.00, 49.20 (recent high). Support at 48.60 (200-DMA), 48.35 (100-DMA), 48.00.

Malaysia Fixed Income

Rates Indicators

MGS	Previous Bus. Day	Yesterday's Close	Change (bps)
3YR MH 3/23	2.12	2.14	+2
5YR MO 9/25	2.59	2.58	-1
7YR MS 6/28	2.97	2.97	Unchanged
10YR MO 4/31	3.12	3.04	-8
15YR MS 7/34	3.79	3.78	-1
20YR MY 5/40	4.06	4.07	+1
30YR MZ 6/50	4.20	4.17	-3
IRS			
6-months	1.96	1.96	-
9-months	1.97	1.97	-
1-year	2.01	2.01	-
3-year	2.43	2.43	-
5-year	2.73	2.70	-3
7-year	2.88	2.84	-4
10-year	3.13	3.07	-6

Analysts

Winson Phoon (65) 6812 8807 winsonphoon@maybank-ke.com.sg

Se Tho Mun Yi (603) 2074 7606 munyi.st@maybank-ib.com

Source: Maybank KE

*Indicative levels

- Govvies continued to strengthen with 10y MGS yield down 8bps to 3.04% while other yields lowered 1-4bps. Trading volume was decent. The 7y MGS 6/28 benchmark reopening auction garnered a modest bid-to-cover ratio of 1.59x on a MYR4.5b issuance size. The average yield was 2.963%, about 8bps below 10y MGS, giving a kink in this part of the curve. Decent liquidity and balanced two-way flows continue to support the market, and sustained real money and foreign demand at the long end could drive the curve flatter.
- The IRS curve flattened as rates lowered 3-6bps along the 5y10y while shorter tenor rates were unchanged. Liquidity was still thin and only 2y IRS dealt at 2.24%. More payers later emerged around the belly near market close. 3M KLIBOR was unchanged at 1.94%.
- PDS market was constructive with high quality credits better bid. GGs traded 3-8bps firmer in yield led by the front end and belly. AAAs were well bid in the same sectors and yields firmer by 1-6bps, with Aman, Danga and Digi traded. AA yields were firmer at the short end by 1-3bps, with trades in Press Metal and UEMS. The momentum could continue given the sustained rally in government bonds. Primary space saw Tropicana Corp raising MYR183m via 5y and 7y ITMNs priced at 5.65% and 5.80% respectively.

Singapore Fixed Income

Rates Indicators

SGS	Previous Bus. Day	Yesterday's Close	Change (bps)
2YR	0.50	0.49	-1
5YR	0.91	0.88	-3
10YR	1.69	1.64	-5
15YR	2.01	1.97	-4
20YR	2.06	2.02	-4
30YR	2.04	2.01	-3

Source: MAS

- Absent any other catalyst, SGD rates tracked UST yields lower. SGD IRS were down by 2-9bps with the 5y10y part of the curve shifting lower in a parallel manner. SGS market saw offers being lifted, but still underperformed UST and SGD IRS with yields lower by just 1-5bps, led by the belly area.
- Asian credits market was weaker despite firm equities. Sovereign bonds were more resilient, though still 2bps wider. China and HK IGs were likely affected by the negative spillover from HRINTH and broad selling sentiment. Tech credits such as Baba and Tencent traded 20bps wider, and Sinopec and Haohua traded 8-15bps wider. Malaysia IGs widened 1-3bps amid muted interest. HRINTH remained under immense pressure as seniors widened as much as 100bps at the belly and perps weakened by 3-5pts. Other AMC names such as CCAMCL/ORIEAS and GRWALL also traded wider by 20bps. China HY property credits were stable on better buying and prices rose 0.50-3pts higher. India HY industrial credits saw prices up by 0.75-1.5pts.

Indonesia Fixed Income

Rates Indicators

IDR Gov't Bonds	Previous Bus. Day	Yesterday's Close	Change	
1YR	3.75	3.75	0.00	
3YR	5.39	5.29	(0.10)	
5YR	5.77	5.67	(0.10)	
10YR	6.58	6.52	(0.06)	
15YR	6.60	6.51	(0.09)	
20YR	7.34	7.33	(0.01)	
30YR	7.05	7.01	(0.04)	

Analysts

Myrdal Gunarto (62) 21 2922 8888 ext 29695 MGunarto@maybank.co.id

* Source: Bloomberg, Maybank Indonesia

Indonesian government bonds continued their rally trends until yesterday. Yesterday, the government successfully absorbed Rp2.655 trillion from its Greenshoe Option. It followed previous day's absorption by Rp7.345 trillion. Hence, the government met its indicative target by Rp10 trillion from its two days' Sukuk auctions. Recent improvement condition on the domestic financial market was also supportive factor for recent government's successful Sukuk auction.

Investors keep seeing attractive yields on Indonesian government bonds after seeing recent modest pace on Indonesian inflation. Moreover, recent surging on the yields of U.S.10Y government notes receded. Investors continued applying strategy of "buy on weakness" to get an advantage of wide gap of net interest from Indonesian investment. We expect global investors to continue entering the emerging markets, such as Indonesia, due to recent positive developments on the national vaccination for COVID-19, modest pace inflation, an increase on manufacturing activities, solid economic recovery in the United States, and strong commitment from the U.S. the government to revive the economy by its extravagant budget. The Federal Reserve also seems to keep being dovish for applying its monetary policy, as shown by its latest meeting minutes. Foreign investors' ownership on Indonesian government bonds are relative lagging so far. It can be key factor for foreigners to come back by aggressively further to Indonesian financial markets, if the global economic condition poses a significant improvement from the negative effects of COVID-19 pandemic. Furthermore, investors will also keep putting strong concerns on further developments of the U.S. Treasury yields, the daily cases of COVID-19, and various geopolitical concerns.

	EUR/USD	USD/JPY	AUD/USD	GBP/USD	USD/CNH	NZD/USD	EUR/JPY	AUD/JPY
R2	1.1935	110.15	0.7707	1.3882	6.5607	0.7098	130.9567	84.5433
R1	1.1902	110.00	0.7660	1.3810	6.5546	0.7056	130.6733	84.0857
Current	1.1869	109.79	0.7617	1.3743	6.5520	0.7010	130.3100	83.6140
S1	1.1848	109.64	0.7584	1.3695	6.5405	0.6984	130.1233	83.3307
S2	1.1827	109.43	0.7555	1.3652	6.5325	0.6954	129.8567	83.0333
	USD/SGD	USD/MYR	USD/IDR	USD/PHP	USD/THB	EUR/SGD	CNY/MYR	SGD/MYR
R2	1.3453	4.1485	14537	48.7380	31.4743	1.5985	0.6318	3.0925
R1	1.3433	4.1400	14516	48.6690	31.4277	1.5951	0.6309	3.0885
Current	1.3410	4.1370	14500	48.6100	31.3900	1.5916	0.6316	3.0855
S1	1.3385	4.1225	14472	48.5190	31.2937	1.5880	0.6295	3.0794
S2	1.3357	4.1135	14449	48.4380	31.2063	1.5843	0.6290	3.0743

Foreign Exchange: Daily Levels

*Values calculated based on pivots, a formula that projects support/resistance for the day.

Policy Rates

Rates	Current (%)	Upcoming CB Meeting	MBB Expectation
MAS SGD 3-Month SIBOR	0.4375	14/4/21	Easing
BNM O/N Policy Rate	1.75	6/5/2021	Easing
BI 7-Day Reverse Repo Rate	3.50	20/4/2021	Easing
BOT 1-Day Repo	0.50	5/5/2021	Easing
BSP O/N Reverse Repo	2.00	13/5/2021	Easing
CBC Discount Rate	1.13	17/6/2021	Easing
HKMA Base Rate	0.50	-	Neutral
PBOC 1Y Lending Rate	4.35	-	Neutral
RBI Repo Rate	4.00	4/6/21	Easing
BOK Base Rate	0.50	15/4/2021	Easing
Fed Funds Target Rate	0.25	29/4/2021	Easing
ECB Deposit Facility Rate	-0.50	22/4/2021	Easing
BOE Official Bank Rate	0.10	6/5/2021	Easing
RBA Cash Rate Target	0.10	4/5/2021	Easing
RBNZ Official Cash Rate	0.25	14/4/2021	Easing
BOJ Rate	-0.10	27/4/2021	Easing
BoC O/N Rate	0.25	21/4/2021	Easing

Equity Indices and Key Commodities

	Value	% Change
Dow	33,446.26	0.05
Nasdaq	13,688.84	-0.07
Nikkei 225	29,730.79	0.12
FTSE	6,885.32	0.91
Australia ASX 200	6,928.02	0.61
Singapore Straits Times	3,195.76	-0.37
Kuala Lumpur Composite	1,600.59	1.37
Jakarta Composite	6,036.62	0.56
P hilippines Composite	6,651.71	0.93
Taiwan TAIEX	16,815.36	0.45
Korea KOSPI	3,137.41	0.33
Shanghai Comp Index	3,479.63	-0.10
Hong Kong Hang Senɑ	28,674.80	-0.91
India Sensex	49,661.76	0.94
Nymex Crude Oil WTI	59.77	0.74
Comex Gold	1,741.60	-0.08
Reuters CRB Index	186.31	0.25
MBB KL	8.48	2.05

🛞 Maybank

MYR Bonds Trades Details						
MGS & GII	Coupon	Maturity Date	Volume (RM 'm)	Last Done	Day High	Day Low
MGS 1/2011 4.16% 15.07.2021	4.160%	15-Jul-21	190	1.751	1.788	1.751
MGS 4/2016 3.620% 30.11.2021	3.620%	30-Nov-21	219	1.795	1.836	1.795
MGS 1/2017 3.882% 10.03.2022	3.882%	10-Mar-22	7	1.818	1.818	1.785
MGS 1/2012 3.418% 15.08.2022	3.418%	15-Aug-22	65	2.024	2.024	1.99
MGS 3/2013 3.480% 15.03.2023	3.480%	15-Mar-23	218	2.131	2.152	2.107
MGS 2/2018 3.757% 20.04.2023	3.757%	20-Apr-23	35	2.118	2.118	2.113
MGS 3/2019 3.478% 14.06.2024	3.478%	14-Jun-24	135	2.346	2.346	2.329
MGS 1/2014 4.181% 15.07.2024	4.181%	15-Jul-24	10	2.426	2.426	2.426
MGS 2/2017 4.059% 30.09.2024	4.059%	30-Sep-24	2	2.466	2.466	2.422
MGS 1/2018 3.882% 14.03.2025	3.882%	14-Mar-25	60	2.537	2.537	2.537
MGS 1/2015 3.955% 15.09.2025	3.955%	15-Sep-25	461	2.59	2.604	2.553
MGS 1/2019 3.906% 15.07.2026	3.906%	15-Jul-26	20	2.677	2.677	2.677
MGS 3/2016 3.900% 30.11.2026	3.900%	30-Nov-26	57	2.651	2.651	2.625
MGS 3/2007 3.502% 31.05.2027	3.502%	31-May-27	21	2.832	2.832	2.797
MGS 4/2017 3.899% 16.11.2027	3.899%	16-Nov-27	33	2.829	2.874	2.829
MGS 5/2013 3.733% 15.06.2028	3.733%	15-Jun-28	642	2.974	2.98	2.92
MGS 2/2019 3.885% 15.08.2029	3.885%	15-Aug-29	199	3.077	3.113	3.052
MGS 3/2010 4.498% 15.04.2030	4.498%	15-Apr-30	11	3.187	3.187	3.175
MGS 2/2020 2.632% 15.04.2031	2.632%	15-Apr-31	230	3.076	3.119	3.04
MGS 4/2011 4.232% 30.06.2031	4.232%	30-Jun-31	73	3.303	3.303	3.248
MGS 4/2013 3.844% 15.04.2033	3.844%	15-Apr-33	2	3.781	3.792	3.755
MGS 3/2018 4.642% 07.11.2033	4.642%	07-Nov-33	1	3.834	3.834	3.834
MGS 4/2019 3.828% 05.07.2034	3.828%	05-Jul-34	78	3.779	3.781	3.608
MGS 4/2015 4.254% 31.05.2035	4.254%	31-May-35	1	3.929	3.929	3.881
MGS 3/2017 4.762% 07.04.2037	4.762%	07-Apr-37	2	4.036	4.159	4.031
MGS 4/2018 4.893% 08.06.2038	4.893%	08-Jun-38	1	4.145	4.145	4.145
MGS 5/2019 3.757% 22.05.2040	3.757%	22-May-40	33	4.083	4.099	4.067
MGS 2/2016 4.736% 15.03.2046	4.736%	15-Mar-46	1	4.413	4.413	4.277
MGS 5/2018 4.921% 06.07.2048	4.921%	06-Jul-48	1	4.423	4.423	4.365
MGS 1/2020 4.065% 15.06.2050 GII MURABAHAH 2/2016 3.743%	4.065%	15-Jun-50	154	4.166	4.227	4.148
26.08.2021	3.743%	26-Aug-21	100	1.769	1.769	1.769
GII MURABAHAH 4/2018 3.729% 31.03.2022 GII MURABAHAH 3/2017 3.948%	3.729%	31-Mar-22	11	1.863	1.868	1.863
14.04.2022	3.948%	14-Apr-22	10	1.915	1.915	1.915
GII MURABAHAH 1/2015 4.194% 15.07.2022 GII MURABAHAH 7/2019 3.151%	4.194%	15-Jul-22	310	2.001	2.001	2.001
15.05.2023 GII MURABAHAH 4/2019 3.655%	3.151%	15-May-23	51	2.159	2.195	2.159
15.10.2024 GII MURABAHAH 3/2019 3.726% 21.02.2024	3.655% 3.726%	15-Oct-24 31-Mar-26	216 393	2.385 2.605	2.417 2.605	2.385 2.542
31.03.2026 GII MURABAHAH 3/2016 4.070% 30.09.2026	4.070%	30-Sep-26	20	2.805	2.805	2.342
GII MURABAHAH 1/2020 3.422% 30.09.2027	3.422%	30-Sep-27	50	2.944	2.944	2.893
GII MURABAHAH 2/2018 4.369% 31.10.2028	4.369%	31-Oct-28	131	3.092	3.092	3.049
GII MURABAHAH 9/2013 06.12.2028	4.943%	06-Dec-28	10	3.055	3.055	3.055
GII MURABAHAH 1/2019 4.130% 09.07.2029	4.130%	09-Jul-29	170	3.099	3.133	3.098
GII MURABAHAH 3/2015 4.245% 30.09.2030	4.245%	30-Sep-30	60	3.163	3.163	3.162
GII MURABAHAH 2/2020 3.465% 15.10.2030	3.465%	15-Oct-30	390	3.152	3.159	3.102
GII MURABAHAH 6/2017 4.724% 15.06.2033	4.724%	15-Jun-33	40	3.835	3.835	3.833

Sources: BDAM						
Total			5,025			
15.11.2049	4.638%	15-Nov-49	20	4.436	4.437	4.436
30.09.2041 GII MURABAHAH 5/2019 4.638%	4.417%	30-Sep-41	80	4.154	4.154	4.129
GII MURABAHAH 2/2021 4.417%						

Sources: BPAM

MYR Bonds Trades Details PDS	Rating	Coupon	Maturity Date	Volume (RM 'm)	Last Done	Day High	Day Low
LPPSA IMTN 2.350% 06.11.2025 - Tranche No 41	GG	2.350%	06-Nov-25	5	2.93	2.93	2.93
PRASARANA IMTN 0% 04.08.2026 - MTN 4	GG	4.350%	04-Aug-26	25	3.052	3.052	3.052
LPPSA IMTN 4.050% 21.09.2026 - Tranche No 4	GG	4.050%	21-Sep-26	15	3.051	3.051	3.051
GOVCO IMTN 4.730% 06.06.2031	GG	4.730%	06-Jun-31	45	3.65	3.701	3.65
PTPTN IMTN 12.03.2032	GG	4.860%	12-Mar-32	10	3.79	3.79	3.79
PTPTN IMTN 4.900% 21.01.2033	GG	4.900%	21-Jan-33	30	3.939	3.95	3.93
DANAINFRA IMTN 5.250% 21.04.2034 - Tranche No 17	GG	5.250%	21-Apr-34	20	4.09	4.09	4.09
DANAINFRA IMTN 4.790% 27.11.2034 - Tranche No 28	GG	4.790%	27-Nov-34	10	4.14	4.14	4.14
LPPSA IMTN 4.620% 19.09.2036 - Tranche No 5	GG	4.620%	19-Sep-36	20	4.361	4.361	4.35
PLUS BERHAD IMTN 4.400% 12.01.2022 - Series 1 (6)	AAA IS	4.400%	12-Jan-22	50	2.423	2.436	2.42
AMAN IMTN 4.130% 12.04.2022 - Tranche No. 16	AAA IS	4.130%	12-Apr-22	10	2.55	2.55	2.55
TELEKOM IMTN 4.550% 07.10.2024	AAA	4.550%	07-Oct-24	10	2.937	2.94	2.93
DANGA IMTN 4.600% 23.02.2026 - Tranche 6	AAA (S)	4.600%	23-Feb-26	20	3.087	3.089	3.08
DIGI IMTN 3.50% 18.09.2026 - Tranche No 4	AAA	3.500%	18-Sep-26	5	3.261	3.261	3.26
DANGA IMTN 4.520% 06.09.2027 - Tranche 7	AAA (S)	4.520%	06-Sep-27	15	3.432	3.432	3.43
TELEKOM IMTN 31.10.2028	AAA	4.680%	31-Oct-28	20	3.7	3.702	3.7
SEB IMTN 4.950% 25.11.2033	AAA	4.950%	25-Nov-33	30	4.418	4.418	4.39
PLUS BERHAD IMTN 5.390% 12.01.2034 - Series 1 (18)	AAA IS	5.390%	12-Jan-34	10	4.409	4.41	4.40
UEMS IMTN 4.80% 08.04.2022 - Issue No. 6	AA- IS	4.800%	08-Apr-22	5	3.687	3.687	3.68
UEMED IMTN 4.850% 26.04.2022	AA- IS	4.850%	26-Apr-22	10	2.916	2.936	2.91
PRESS METAL IMTN 4.000% 15.08.2025	AA3	4.000%	15-Aug-25	10	4.271	4.281	4.27
MMC CORP IMTN 5.800% 12.11.2025	AA- IS	5.800%	12-Nov-25	10	3.998	4.001	3.99
GLT12 IMTN 3.750% 12.08.2027	AA3 (S)	3.750%	12-Aug-27	10	4.217	4.222	4.21
SPG IMTN 5.610% 31.10.2035	AA- IS	5.610%	31-Oct-35	10	4.561	4.561	4.56
LCSB IMTN 4.400% 11.12.2023	A1	4.400%	11-Dec-23	4	4.336	4.34	4.33
EWIB IMTN 6.650% 27.04.2023	NR(LT)	6.650%	27-Apr-23	1	5.736	5.736	5.73
ECO CAPITAL MTN 6.10% 13.8.2024	NR(LT)	6.100%	13-Aug-24	2	5.518	5.751	5.51

Sources: BPAM

DISCLAIMER

This report is for information purposes only and under no circumstances is it to be considered or intended as an offer to sell or a solicitation of an offer to buy the securities or financial instruments referred to herein, or an offer or solicitation to any person to enter into any transaction or adopt any investment strategy. Investors should note that income from such securities or financial instruments, if any, may fluctuate and that each security's or financial instrument's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. This report is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this report. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities and/or financial instruments or the investment strategies discussed or recommended in this report.

The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Malayan Banking Berhad and/or its affiliates and related corporations (collectively, "Maybank") and consequently no representation is made as to the accuracy or completeness of this report by Maybank and it should not be relied upon as such. Accordingly, no liability can be accepted for any direct, indirect or consequential losses or damages that may arise from the use or reliance of this report. Maybank and its officers, directors, associates, connected parties and/or employees may from time to time have positions or be materially interested in the securities and/or financial instruments referred to herein and may further act as market maker or have assumed an underwriting commitment or deal with such securities and/or financial instruments and may also perform or seek to perform investment banking, advisory and other services for or relating to those companies whose securities are mentioned in this report. Any information or opinions or recommendations contained herein are subject to change at any time, without prior notice.

This report may contain forward looking statements which are often but not always identified by the use of words such as "anticipate", "believe", "estimate", "intend", "plan", "expect", "forecast", "predict" and "project" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward looking statements. Readers are cautioned not to place undue relevance on these forward looking statements. Maybank expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

This report is prepared for the use of Maybank's clients and may not be reproduced, altered in any way, transmitted to, copied or distributed to any other party in whole or in part in any form or manner without the prior express written consent of Maybank. Maybank accepts no liability whatsoever for the actions of third parties in this respect. This report is not directed to or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

APPENDIX I: TERMS FOR PROVISION OF REPORT, DISCLAIMERS AND DISCLOSURES

DISCLAIMERS

This research report is prepared for general circulation and for information purposes only and under no circumstances should it be considered or intended as an offer to sell or a solicitation of an offer to buy the securities referred to herein. Investors should note that values of such securities, if any, may fluctuate and that each security's price or value may rise or fall. Opinions or recommendations contained herein are in form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from the relevant jurisdiction's stock exchange in the equity analysis. Accordingly, investors' returns may be less than the original sum invested. Past performance is not necessarily a guide to future performance. This report is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this report. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

The information contained herein has been obtained from sources believed to be reliable but such sources have not been independently verified by Maybank Investment Bank Berhad, its subsidiary and affiliates (collectively, "MKE") and consequently no representation is made as to the accuracy or completeness of this report by MKE and it should not be relied upon as such. Accordingly, MKE and its officers, directors, associates, connected parties and/or employees (collectively, "Representatives") shall not be liable for any direct, indirect or consequential losses or damages that may arise from the use or reliance of this report. Any information, opinions or recommendations contained herein are subject to change at any time, without prior notice.

This report may contain forward looking statements which are often but not always identified by the use of words such as "anticipate", "believe", "estimate", "intend", "plan", "expect", "forecast", "predict" and "project" and statements that an event or result "may", "will", "can", "should", "could" or "might" occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. MKE expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

MKE and its officers, directors and employees, including persons involved in the preparation or issuance of this report, may, to the extent permitted by law, from time to time participate or invest in financing transactions with the issuer(s) of the securities mentioned in this report, perform services for or solicit business from such issuers, and/or have a position or holding, or other material interest, or effect transactions, in such securities or options thereon, or other investments related thereto. In addition, it may make markets in the securities mentioned in the material presented in this report. One or more directors, officers and/or employees of MKE may be a director of the issuers of the securities mentioned in this report to the extent permitted by law.

This report is prepared for the use of MKE's clients and may not be reproduced, altered in any way, transmitted to, copied or distributed to any other party in whole or in part in any form or manner without the prior express written consent of MKE and MKE and its Representatives accepts no liability whatsoever for the actions of third parties in this respect.

This report is not directed to or intended for distribution to or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. This report is for distribution only under such circumstances as may be permitted by applicable law. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

Malaysia

Opinions or recommendations contained herein are in the form of technical ratings and fundamental ratings. Technical ratings may differ from fundamental ratings as technical valuations apply different methodologies and are purely based on price and volume-related information extracted from Bursa Malaysia Securities Berhad in the equity analysis.

Singapore

This report has been produced as of the date hereof and the information herein may be subject to change. Maybank Kim Eng Research Pte. Ltd. ("Maybank KERPL") in Singapore has no obligation to update such information for any recipient. For distribution in Singapore, recipients of this report are to contact Maybank KERPL in Singapore in respect of any matters arising from, or in connection with, this report. If the recipient of this report is not an accredited investor, expert investor or institutional investor (as defined under Section 4A of the Singapore Securities and Futures Act), Maybank KERPL shall be legally liable for the contents of this report, with such liability being limited to the extent (if any) as permitted by law.

Thailand

Except as specifically permitted, no part of this presentation may be reproduced or distributed in any manner without the prior written permission of Maybank Kim Eng Securities (Thailand) Public Company Limited ("MBKET") accepts no liability whatsoever for the actions of third parties in this respect.

Due to different characteristics, objectives and strategies of institutional and retail investors, the research products of MBKET Institutional and Retail Research departments may differ in either recommendation or target price, or both. MBKET reserves the rights to disseminate MBKET Retail Research reports to institutional investors who have requested to receive it. If you are an authorised recipient, you hereby tacitly acknowledge that the research reports from MBKET Retail Research are first produced in Thai and there is a time lag in the release of the translated English version.

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey may be changed after that date. MBKET does not confirm nor certify the accuracy of such survey result.

The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by Thaipat Institute, is made in order to comply with the policy and sustainable development plan for the listed companies of the Office of the Securities and Exchange Commission. Thaipat Institute made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of Thaipat Institute that is a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, MBKET does not confirm, verify, or certify the accuracy and completeness of the assessment result.

US

This third-party research report is distributed in the United States ("US") to Major US Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended) only by Maybank Kim Eng Securities USA Inc ("Maybank KESUSA"), a broker-dealer registered in the US (registered under Section 15 of the Securities Exchange Act of 1934, as amended). All responsibility for the distribution of this report by Maybank KESUSA in the US shall be borne by Maybank KESUSA. This report is not directed at you if MKE is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you. You should satisfy yourself before reading it that Maybank KESUSA is permitted to provide research material concerning investments to you under relevant legislation and regulations. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security mentioned within must do so with: Maybank Kim Eng Securities USA Inc. 400 Park Avenue, 11th Floor, New York, New York 10022, 1-(212) 688-8886 and not with, the issuer of this report.

UK

This document is being distributed by Maybank Kim Eng Securities (London) Ltd ("Maybank KESL") which is authorized and regulated, by the Financial Conduct Authority and is for Informational Purposes only. This document is not intended for distribution to anyone defined as a Retail Client under the Financial Services and Markets Act 2000 within the UK. Any inclusion of a third party link is for the recipients convenience only, and that the firm does not take any responsibility for its comments or accuracy, and that access to such links is at the individuals own risk. Nothing in this report should be considered as constituting legal, accounting or tax advice, and that for accurate guidance recipients should consult with their own independent tax advisers.

DISCLOSURES

Legal Entities Disclosures

Malaysia: This report is issued and distributed in Malaysia by Maybank Investment Bank Berhad (15938- H) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets and Services License issued by the Securities Commission in Malaysia. Singapore: This report is distributed in Singapore by Maybank KERPL (Co. Reg No 198700034E) which is regulated by the Monetary Authority of Singapore. Indonesia: PT Maybank Kim Eng Securities ("PTMKES") (Reg. No. KEP-251/PM/1992) is a member of the Indonesia Stock Exchange and is regulated by the Financial Services Authority (Indonesia). Thailand: MBKET (Reg. No.0107545000314) is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission. Philippines: Maybank ATRKES (Reg. No.01-2004-00019) is a member of the Philippines Stock Exchange and is regulated by the Securities and Exchange Commission. Vietnam: Maybank Kim Eng Securities Limited (License Number: 117/GP-UBCK) is licensed under the State Securities Commission of Vietnam. Hong Kong: KESHK (Central Entity No AAD284) is regulated by the Securities and Exchange Board of India ("SEBI") (Reg. No. INZ000010538). KESI is also registered with SEBI as Category 1 Merchant Banker (Reg. No. INM 000011708) and as Research Analyst (Reg No: INH000000057) US: Maybank KESUSA is a member of / and is authorized and regulated by the FINRA - Broker ID 27861. UK: Maybank KESL (Reg No 2377538) is authorized and regulated by the Financial Conduct Authority.

Disclosure of Interest

Malaysia: MKE and its Representatives may from time to time have positions or be materially interested in the securities referred to herein and may further act as market maker or may have assumed an underwriting commitment or deal with such securities and may also perform or seek to perform investment banking services, advisory and other services for or relating to those companies.

Singapore: As of 8 April 2021, Maybank KERPL and the covering analyst do not have any interest in any companies recommended in this research report.

Thailand: MBKET may have a business relationship with or may possibly be an issuer of derivative warrants on the securities /companies mentioned in the research report. Therefore, Investors should exercise their own judgment before making any investment decisions. MBKET, its associates, directors, connected parties and/or employees may from time to time have interests and/or underwriting commitments in the securities mentioned in this report.

Hong Kong: As of 8 April 2021, KESHK and the authoring analyst do not have any interest in any companies recommended in this research report.

India: As of 8 April 2021, and at the end of the month immediately preceding the date of publication of the research report, KESI, authoring analyst or their associate / relative does not hold any financial interest or any actual or beneficial ownership in any shares or having any conflict of interest in the subject companies except as otherwise disclosed in the research report.

In the past twelve months KESI and authoring analyst or their associate did not receive any compensation or other benefits from the subject companies or third party in connection with the research report on any account what so ever except as otherwise disclosed in the research report.

MKE may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment and may receive compensation for the services provided from the companies covered in this report.

OTHERS

Analyst Certification of Independence

The views expressed in this research report accurately reflect the analyst's personal views about any and all of the subject securities or issuers; and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.

Reminder

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct its own analysis of the product and consult with its own professional advisers as to the risks involved in making such a purchase.

No part of this material may be copied, photocopied or duplicated in any form by any means or redistributed without the prior consent of MKE.

Published by:



Malayan Banking Berhad (Incorporated In Malaysia)

Foreign Exchange <u>Singapore</u> Saktiandi Supaat Head, FX Research saktiandi@maybank.com.sg (+65) 6320 1379

Christopher Wong Senior FX Strategist Wongkl@maybank.com.sg (+65) 6320 1347

Fiona Lim Senior FX Strategist Fionalim@maybank.com.sg (+65) 6320 1374

Yanxi Tan FX Strategist tanyx@maybank.com.sg (+65) 6320 1378

Fixed Income <u>Malaysia</u> Winson Phoon Wai Kien Fixed Income Analyst winsonphoon@maybank-ke.com.sg (+65) 6340 1079

> Se Tho Mun Yi Fixed Income Analyst munyi.st@maybank-ib.com (+60) 3 2074 7606

Indonesia Juniman Chief Economist, Indonesia juniman@maybank.co.id (+62) 21 2922 8888 ext 29682

Myrdal Gunarto Industry Analyst MGunarto@maybank.co.id (+62) 21 2922 8888 ext 29695

Sales

<u>Malaysia</u> Azman Amiruddin Shah bin Mohamad Shah Head, Sales-Malaysia, GB-Global Markets azman.shah@maybank.com (+60) 03-2173 4188

> <u>Singapore</u> Janice Loh Ai Lin Head of Sales, Singapore jloh@maybank.com.sg (+65) 6536 1336

Indonesia Endang Yulianti Rahayu Head of Sales, Indonesia EYRahayu@maybank.co.id (+62) 21 29936318 or (+62) 2922 8888 ext 29611

<u>Shanghai</u> Joyce Ha Treasury Sales Manager Joyce.ha@maybank.com (+86) 21 28932588

<u>Hong Kong</u> Joanne Lam Sum Sum Head of Corporate Sales Hong Kong Joanne.lam@maybank.com (852) 3518 8790